Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19

Inclusion Criteria: * Patient is in HMC facility for low-acuity, Covid-positive patients being quarantined. * Positive Covid test on qualitative assay used during routine care (i.e. not as part of Q-PROTECT) * Age at least 18 Exclusion Criteria: * Treating physician judges patient not appropriate for study participation for any reason * Age \<18 * Breastfeeding or pregnancy (patient-reported pregnancy status is sufficient) * Hypersensitivity to chloroquine or HC or AZ * History of or known QT prolongation * EKG required before study entry and on each visit during the subject's first seven days on pro-tocol, during the time period HC is being taken * Baseline QTc \>480 if QRS width normal; QTc \>510 if QRS \>120 * Known G6PD deficiency, porphyria, or retinopathy (eye exam prior to study entry) * Known hepatic or renal disease (or abnormality on liver or renal function testing at study day 1) * Low magnesium or low potassium (by testing on day 1) * Current (pre-study) therapy with antimalarial or dapsone * Current (pre-study) therapy with antiviral agents (e.g. oseltamivir) * Tisdale36 score exceeding 6 as tallied below (based on ACC recommendations)\* * 1 point each: age\>67, female sex, or being on loop diuretic * 2 points each: serum potassium \<3.6, QTc\>449, acute myocardial infarction * 3 points each: sepsis, heart failure, QT-prolonging drugs